Toshiya Hari: Thank you for all the color.
Brice Hill: Yeah.
Operator: Thank you. Our next question comes from the line of Harlan Sur of JPMorgan.
Harlan Sur: Good afternoon. Thanks for taking my question. Team has been doing very well in process control. It’s about 10% to 12% of your systems business. I think it grew above 55%, 60% faster than your overall systems business last year. Gary, you talked about strong technology inflections and benefits across the wafer equipment portfolio, but I’m assuming this is also pulling strong requirements for more and better process controls. So with that, I mean, can you just give us an update on process control portfolio? And how is that segment performing relative to your overall systems business this year?
Gary Dickerson: Hi, Harlan. Yeah, thanks for the question. So, PDC for us, there are really two major areas of focus. One is, as you’ve talked about, is growth within PDC, but the other thing that is increasingly important is the synergy with PDC and our process equipment, both for unit equipment and integrated material solutions, accelerating R&D for some of these major inflections. So, on the PDC growth, the business grew about two times between 2020 and 2022. eBeam is one of the fastest growing segments there. And we’ve maintained our leadership with around 50% overall share in eBeam. We have new products coming to market. We’ve talked about in our Master Class, the cold field emission with the highest resolution and fastest imaging.
So that’s helping that business growth. And then on the synergy, we had discussed the capacitor formation of DRAM where we’re bringing new materials, new etching solutions together with eBeam technology, again, to accelerate those inflections nanosheets and Gate-All-Around. These technologies are incredibly complex. And you can’t fix what you can’t see. In our eBeam, imaging is world-class, ahead of anyone else. And so that synergy value is increasing. That will also help our growth in our market share overall in our semiconductor product group, but in PDC. So again, we’re really in a great position, strong pipeline of products coming in PDC and great synergies with overall Applied.
Harlan Sur: Great insights. Thank you.
Operator: Thank you. Standby for our next question. And our next question comes from the line of Timothy Arcuri of UBS Securities.
Timothy Arcuri: Thanks a lot. I had a two-part question. First of all, Brice, can you give us a sense of, of the $1.7 billion that’s in July for China revenue, can you tell us how much of that is domestic China chip makers versus other multis that might have fabs in China, but they’re not domestic Chinese chip makers? And then the part two of the question is, how do you handicap the potential that this China [DRAMs pull in] (ph)? I mean, we have Micron that’s been banned in China. We have a China memory maker now taking $500 million more worth of your tools in October versus July; that’s $2 billion to $2.5 billion worth of extra WFE that’s just in that one quarter. So, how do you handicap sort of how you run production factory? Do you count on that being sustained? Do you think that it’s possible that it could be a pull in? If you can just comment on that? Thanks.
Brice Hill: Sure. Thanks for the questions, Tim. So, on the $1.7 billion for China, about 27% of our revenue, it’s almost all. It’s not a 100%, but it’s almost all domestic Chinese customers; very little on the multinational, at this point. And then — and just a reminder, it does include, a portion of our Services business. It does include a portion of our Display business in that number also. And then on the handicapping, whether it’s a pull in for the traditional or legacy DRAM, I certainly don’t think it’s a pull in. This is a technology that was viewed as not being part of the rules where technologies were restricted for China. So, it’s an existing technology. I think they’ll put that equipment into operation as quickly as possible.
